Screener
MapLight Therapeutics, Inc. MPLT Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income, net: | ||
| Interest income | 2,472 | 811 |
| Other income, net | 1,363 | 392 |
| Net loss | $(60,668) | $(22,340) |
| Net loss per share - basic and diluted | $(1.34) | $(29.33) |
| Weighted-average number of common shares outstanding - basic and diluted | 45,276,763 | 761,598 |
| Comprehensive loss: | ||
| Net loss | $(60,668) | $(22,340) |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s net income?
- MapLight Therapeutics, Inc. (MPLT) reported net income of -$60.67M in Q1 2026.
- How has MapLight Therapeutics, Inc.'s net income changed year-over-year?
- MapLight Therapeutics, Inc.'s net income decreased by 171.6% year-over-year, from -$22.34M to -$60.67M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about MapLight Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude